0
Article ? AI-assigned paper type based on the abstract. Classification may not be perfect — flag errors using the feedback button. Tier 2 ? Original research — experimental, observational, or case-control study. Direct primary evidence. Human Health Effects Policy & Risk Sign in to save

Nano- and microplastic PBK modeling in the context of human exposure and risk assessment

Environment International 2024 33 citations ? Citation count from OpenAlex, updated daily. May differ slightly from the publisher's own count. Score: 65 ? 0–100 AI score estimating relevance to the microplastics field. Papers below 30 are filtered from public browse.
Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Nur Hazimah Mohamed Nor, Nur Hazimah Mohamed Nor, Nur Hazimah Mohamed Nor, Nur Hazimah Mohamed Nor, Ira Wardani, Ira Wardani, Ira Wardani, Ira Wardani, Ira Wardani, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Stephanie Wright Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Stephanie Wright Stephanie Wright Stephanie Wright Stephanie Wright Albert A. Koelmans, Stephanie Wright Stephanie Wright Stephanie Wright Stephanie Wright Stephanie Wright Stephanie Wright Stephanie Wright Stephanie Wright Stephanie Wright Ingeborg M. Kooter, Nur Hazimah Mohamed Nor, Nur Hazimah Mohamed Nor, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Nur Hazimah Mohamed Nor, Nur Hazimah Mohamed Nor, Ira Wardani, Albert A. Koelmans, Albert A. Koelmans, Stephanie Wright Stephanie Wright Albert A. Koelmans, Stephanie Wright Stephanie Wright Stephanie Wright Stephanie Wright Albert A. Koelmans, Nur Hazimah Mohamed Nor, Nur Hazimah Mohamed Nor, Albert A. Koelmans, Nur Hazimah Mohamed Nor, Nur Hazimah Mohamed Nor, Albert A. Koelmans, Albert A. Koelmans, Stephanie Wright Stephanie Wright Stephanie Wright Stephanie Wright Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Nur Hazimah Mohamed Nor, Nur Hazimah Mohamed Nor, Nur Hazimah Mohamed Nor, Nur Hazimah Mohamed Nor, Nur Hazimah Mohamed Nor, Ingeborg M. Kooter, Ingeborg M. Kooter, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Nur Hazimah Mohamed Nor, Stephanie Wright Stephanie Wright Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Ingeborg M. Kooter, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Stephanie Wright Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Ira Wardani, Stephanie Wright Ira Wardani, Albert A. Koelmans, Albert A. Koelmans, Ira Wardani, Ira Wardani, Ira Wardani, Albert A. Koelmans, Ira Wardani, Stephanie Wright Stephanie Wright Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Ingeborg M. Kooter, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Ingeborg M. Kooter, Stephanie Wright Stephanie Wright Stephanie Wright Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Ingeborg M. Kooter, Albert A. Koelmans, Albert A. Koelmans, Stephanie Wright Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Nur Hazimah Mohamed Nor, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Stephanie Wright Stephanie Wright Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Ingeborg M. Kooter, Albert A. Koelmans, Ingeborg M. Kooter, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Stephanie Wright Albert A. Koelmans, Ingeborg M. Kooter, Ingeborg M. Kooter, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Stephanie Wright Albert A. Koelmans, Stephanie Wright Albert A. Koelmans, Albert A. Koelmans, Stephanie Wright Albert A. Koelmans, Stephanie Wright Albert A. Koelmans, Stephanie Wright Ingeborg M. Kooter, Albert A. Koelmans, Ingeborg M. Kooter, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Albert A. Koelmans, Ira Wardani, Albert A. Koelmans, Albert A. Koelmans, Stephanie Wright Stephanie Wright Albert A. Koelmans, Ingeborg M. Kooter, Stephanie Wright Albert A. Koelmans, Stephanie Wright Stephanie Wright Stephanie Wright

Summary

This review evaluates how computer models that simulate the movement of chemicals through the human body (called PBK models) can be applied to nano- and microplastics to better assess health risks. The authors found that most existing studies on plastic particle behavior in the body have significant quality gaps, making reliable risk assessment difficult. The paper proposes a framework for building better models, which is an important step toward understanding what micro- and nanoplastics actually do once they enter the human body.

Models

Insufficient data on nano- and microplastics (NMP) hinder robust evaluation of their potential health risks. Methodological disparities and the absence of established toxicity thresholds impede the comparability and practical application of research findings. The diverse attributes of NMP, such as variations in sizes, shapes, and compositions, complicate human health risk assessment. Although probability density functions (PDFs) show promise in capturing this diversity, their integration into risk assessment frameworks is limited. Physiologically based kinetic (PBK) models offer a potential solution to bridge the gap between external exposure and internal dosimetry for risk evaluation. However, the heterogeneity of NMP poses challenges for accurate biodistribution modeling. A literature review, encompassing both experimental and modeling studies, was conducted to examine biodistribution studies of monodisperse micro- and nanoparticles. The literature search in PubMed and Scopus databases yielded 39 studies that met the inclusion criteria. Evaluation criteria were adapted from previous Quality Assurance and Quality Control (QA-QC) studies, best practice guidelines from WHO (2010), OECD guidance (2021), and additional criteria specific to NMP risk assessment. Subsequently, a conceptual framework for a comprehensive NMP-PBK model was developed, addressing the multidimensionality of NMP particles. Parameters for an NMP-PBK model are presented. QA-QC evaluations revealed that most experimental studies scored relatively well (>0) in particle characterizations and environmental settings but fell short in criteria application for biodistribution modeling. The evaluation of modeling studies revealed that information regarding the model type and allometric scaling requires improvement. Three potential applications of PDFs in PBK modeling of NMP are identified: capturing the multidimensionality of the NMP continuum, quantifying the probabilistic definition of external exposure, and calculating the bio-accessibility fraction of NMP in the human body. A framework for an NMP-PBK model is proposed, integrating PDFs to enhance the assessment of NMP's impact on human health.

Sign in to start a discussion.

Share this paper